Logo jurisLogo Bundesministerium der Justiz und für Verbraucherschutz

Medicinal Products Act
(Arzneimittelgesetz – AMG)

Full text in format:   HTML  PDF   text in German

Übersetzung durch den Sprachendienst des Bundesministeriums für Gesundheit.

Translation provided by the Language Service of the Federal Ministry of Health.

Stand: Die Übersetzung berücksichtigt die Änderung(en) des Gesetzes durch Artikel 3 des Gesetzes vom 4.4.2016 (BGBl. I S. 569)
Der Stand der deutschsprachigen Dokumentation kann aktueller sein. Vergleichen Sie dazu bitte http://www.gesetze-im-internet.de/amg_1976/BJNR024480976.html.

Version information: The translation includes the amendment(s) to the Act by Article 3 of the Act of 4.4.2016 (Federal Law Gazette I p. 569)
Translations may not be updated at the same time as the German legal provisions displayed on this website. To compare with the current status of the German version, see http://www.gesetze-im-internet.de/amg_1976/BJNR024480976.html.

Translations of any materials into languages other than German are intended solely as a convenience to the non-German-reading public. If any questions arise related to the accuracy of the information contained in the translation, please refer to the German version of the document which is the official version of the document. Any discrepancies or differences created in the translation are not binding and have no legal effect for compliance or enforcement purposes.

© 2017 juris GmbH, Saarbrücken

           
FIRST CHAPTER
Purpose of the Act, definition of terms, scope
Section 1Purpose of the Act,
Section 2The term ‘medicinal product’
Section 3The term ‘substance’
Section 4Definition of additional terms
Section 4aExceptions to the scope of the present Act
Section 4bSpecial provisions governing advanced therapy medicinal products
SECOND CHAPTER
Requirements on medicinal products
Section 5 Prohibition in respect of unsafe medicinal products
Section 6 Empowerment in respect of health protection
Section 6a(repealed)
Section 7 Radiopharmaceuticals and medicinal products treated with ionizing radiation
Section 8 Prohibitions to prevent deception
Section 9 The party responsible for placing on the market
Section 10 Labelling
Section 11 Package leaflet
Section 11a Expert information
Section 12 Empowerment in respect of labelling, package leaflet and package sizes
THIRD CHAPTER
MANUFACTURE OF MEDICINAL PRODUCTS
Section 13Manufacturing authorisation
Section 14 Decision on the manufacturing authorisation
Section 15 Expert knowledge
Section 16 Limitation of the manufacturing authorisation
Section 17 Deadlines for the granting of marketing authorisations
Section 18 Withdrawal, revocation, suspension
Section 19 Areas of responsibility
Section 20 Obligations to notify
Section 20aApplicability to active substances and other substances
Section 20bAuthorisation for the procurement of tissues and the pertinent laboratory testing
Section 20cAuthorisation for the processing, preservation, testing and storage or the placing on the market of tissues or preparations made from tissues
Section 20dException from the obligation to obtain an authorisation for tissues and tissue preparations
FOURTH CHAPTER
MARKETING AUTHORISATION OF MEDICINAL PRODUCTS
Section 21Obligation to obtain a marketing authorisation
Section 21aAuthorisation of tissue preparations
Section 22 Marketing authorisation documents
Section 23Particular documents required for medicinal products intended for administration to animals
Section 24 Expert opinions
Section 24aUse of a previous applicant's documents
Section 24bAuthorisation of a generic medicinal product, document protection
Section 24c Additional requests
Section 24d General right of use
Section 25 Decision on marketing authorisation
Section 25a Prior examination
Section 25b Mutual-recognition procedure and decentralised procedure
Section 25cMeasures taken by the competent higher federal authority on decisions or resolutions of the European Community or the European Union
Section 26 Guidelines for the testing of medicinal products
Section 27 Deadlines for the granting of marketing authorisations
Section 28 Power to impose conditions
Section 29 Obligation to notify, renewal of the marketing authorisation
Section 30 Withdrawal, revocation, suspension
Section 31 Expiry, prolongation
Section 32 Official batch testing
Section 33 Fees and expenses
Section 34 Informing the public
Section 35 Empowerments in respect of marketing authorisation and exemptions
Section 36 Empowerment in respect of standard marketing authorisations
Section 37Authorisation by the European Community or the European Union for placing on the market, marketing authorisation of medicinal products from other states
FIFTH CHAPTER
REGISTRATION OF MEDICINAL PRODUCTS
Section 38 Registration of homeopathic medicinal products
Section 39 Decision on the registration of homeopathic medicinal products, procedural provisions
Section 39aRegistration of traditional herbal medicinal products
Section 39bRegistration documents for traditional herbal medicinal products
Section 39cDecision on the registration of traditional herbal medicinal products
Section 39dOther procedural provisions for traditional herbal medicinal products
SIXTH CHAPTER
PROTECTION OF HUMAN SUBJECTS IN CLINICAL TRIALS
Section 40 General conditions for clinical trials
Section 41Special pre-conditions for clinical trials
Section 42Ethics committee procedure, procedure for authorisation by the higher federal authority
Section 42aWithdrawal, revocation and suspension of the authorisation or of the favourable opinion
Section 42bPublication of the results of clinical trials
SEVENTH CHAPTER
SALE OF MEDICINAL PRODUCTS
Section 43Pharmacy-only requirement, placing on the market by veterinarians
Section 44 Exceptions to the pharmacy-only requirement
Section 45 Authority to allow further exceptions to the pharmacy-only requirement
Section 46 Authority to extend the pharmacy-only requirement
Section 47Distribution channel
Section 47aSpecial distribution channels, obligation to keep records
Section 47bSpecial distribution channels, diamorphine
Section 48Prescription requirement
Section 49 (no longer applicable)
Section 50 Retail trading of over-the-counter medicinal products
Section 51 Sale by itinerant traders
Section 52 Prohibition of self-service
Section 52a Wholesale trading of medicinal products
Section 52bSupply of medicinal products
Section 52cBrokering of medicinal products
Section 53 Expert consultation
EIGHTH CHAPTER
SAFETY AND QUALITY CONTROL
Section 54Internal regulations
Section 55 Pharmacopoeia
Section 55aOfficial compilation of test procedures
NINTH CHAPTER
SPECIAL PROVISIONS FOR MEDICINAL PRODUCTS INTENDED FOR USE IN ANIMALS
Section 56Medicated feeding stuffs
Section 56aPrescription, dispensing and use of medicinal products by veterinarians
Section 56bExceptions
Section 57Acquisition and possession by keepers of animals, records
Section 57aUse by animal keepers
Section 58 Use in food-producing animals
Section 58a*Notifications about animal keeping
Section 58bNotifications about the use of medicinal products
Section 58cDetermining the treatment frequency
Section 58dReduction in treatment with antibacterially active substances
Section 58eAuthority to issue ordinances
Section 58fUse of data
Section 58gEvaluation
Section 59 Clinical trial and residue testing in food-producing animals
Section 59aTrade in substances and preparations from substances
Section 59b Substances for conducting residue tests
Section 59cObligations to keep records of substances which can be used as veterinary medicinal products
Section 59dAdministration of pharmacologically active substances to food-producing animals
Section 60 Pet animals
Section 61 Powers of veterinary schools
TENTH CHAPTER
PHARMACOVIGILANCE
Section 62 Organisation of the pharmacovigilance system of the competent higher federal authority
Section 63 Graduated plan
Section 63a Graduated plan officer
Section 63bGeneral pharmacovigilance obligations of the marketing authorisation holder
Section 63c*Documentation and reporting obligations of the holder of a marketing authorisation for medicinal products for human use in the case of suspected adverse reactions
Section 63d*Periodic safety update reports
Section 63eEuropean procedure
Section 63fGeneral prerequisites for non-interventional post-authorisation safety studies
Section 63gSpecial prerequisites for imposed non-interventional post-authorisation safety studies
Section 63hDocumentation and notification obligations for medicinal products for animal use
Section 63iDocumentation and notification obligations in respect of blood and tissue preparations and tissues
Section 63jExceptions
ELEVENTH CHAPTER
Surveillance
Section 64 Conducting supervision
Section 65Sampling
Section 66 Obligation to tolerate and collaborate
Section 67*General notification requirement
Section 67aDatabase-supported information system
Section 68 Obligation to inform and to report
Section 69 Measures by the competent authorities
Section 69aThe supervision of substances which can be used as medicinal products for animals
Section 69bUse of specific data
TWELFTH CHAPTER
Special provisions for the Federal Armed Forces, Federal Police, Public Order Police, Civil Protection
Section 70 Application and enforcement of the Act
Section 71 Exceptions
THIRTEENTH CHAPTER
Import and export
Section 72 Import authorisation
Section 72aCertificates
Section 72bImport authorisations and certificates for tissues and specific tissue preparations
Section 73 Prohibition of introduction
Section 73a Export
Section 74 Participation of customs offices
FOURTEENTH CHAPTER
Information Officer, Pharmaceutical Consultant
Section 74aInformation Officer
Section 75 Expert knowledge
Section 76 Duties
FIFTEENTH CHAPTER
Designation of the competent higher federal authorities and other provisions
Section 77Competent higher federal authority
Section 77aIndependence and transparency
Section 78 Prices
Section 79 Authority to permit exceptions in times of crisis
Section 80 Authority to issue procedural and compassionate use regulations
Section 81 Relation to other laws
Section 82 General administrative regulations
Section 83 Approximation to European Union legislation
Section 83aOrdinances for specific cases
Section 83bPublication of ordinances
Sixteenth Chapter
Liability for damages caused by medicinal products
Section 84 Absolute liability
Section 84a Right to disclosure
Section 85 Contributory negligence
Section 86 Extent of liability for damages in the case of death
Section 87 Extent of liability for damages in the case of bodily injury
Section 88 Maximum amounts
Section 89 Compensation in the form of annuities
Section 90 Statute of limitations (repealed)
Section 91 Extended liability
Section 92 Mandatory provision
Section 93 Several parties liable for damages
Section 94 Coverage provision
Section 94a Local jurisdiction
Seventeenth Chapter
Penal provisions and provisions on administrative fines
Section 95 Penal provisions
Section 96Penal provisions
Section 97Provisions on administrative fines
Section 98 Confiscation
Section 98aExtended forfeiture
Eighteenth Chapter
Transitional and interim provisions
First sub-chapter
Transitional provisions arising out of the Law on the Reform of Drug Legislation
Section 991961 Drug Law
Section 100
Section 101(no longer applicable)
Section 102
Section 102a(no longer applicable)
Section 103
Section 104(no longer applicable)
Section 105
Section 105a
Section 105b
Section 106(no longer applicable)
Section 107(no longer applicable)
Section 108(no longer applicable)
Section 108a
Section 108b (no longer applicable)
Section 109
Section 109a
Section 110
Section 111(no longer applicable)
Section 112
Section 113
Section 114(no longer applicable)
Section 115
Section 116
Section 117(no longer applicable)
Section 118
Section 119
Section 120
Section 121(no longer applicable)
Section 122
Section 123
Section 124
Second sub-chapter
Section 125Transitional provisions arising out of the First Act Amending the Drug Law
Section 126
Third sub-chapter
Transitional provisions arising out of the Second Act Amending the Drug Law
Section 127
Section 128
Section 129
Section 130
Section 131
Fourth sub-chapter
Transitional provisions arising out of the Fifth Act Amending the Drug Law
Section 132
Fifth sub-chapter
Transitional provisions arising of the Seventh Act Amending the Drug Law
Section 133
Sixth sub-chapter
Transitional provisions arising out of the Transfusion Act
Section 134
Seventh sub-chapter
Transitional provisions arising out of the Eighth Act Amending the Drug Law
Section 135
Eighth sub-chapter
Transitional provisions arising out of the Tenth Act Amending the Drug Law
Section 136
Ninth sub-chapter
Transitional provisions arising out of the Eleventh Act Amending the Drug Law
Section 137
Tenth sub-chapter
Transitional provisions arising out of the Twelfth Act Amending the Drug Law
Section 138
Eleventh sub-chapter
Transitional provisions arising out of the First Act Amending the Transfusion Act and the Regulations on Medicinal Products
Section 139
Twelfth sub-chapter
Transitional provisions arising out of the Thirteenth Act Amending the Drug Law
Section 140
Thirteenth sub-chapter
Transitional provisions arising out of the Fourteenth Act Amending the Drug Law
Section 141
Fourteenth sub-chapter
Section 142 Transitional provisions arising out of the Tissues Act
Fifteenth sub-chapter
Section 143*Transitional provisions arising out of the Act on improving measures against doping in sport
Sixteenth sub-chapter
Section 144Transitional provisions arising out of the Act amending the regulations on medicinal products and other regulations
Seventeenth sub-chapter
Section 145Transitional provisions arising out of the Act on the Reform of the Market for Medicinal Products
Eighteenth sub-chapter
Transitional provision
Section 146Transitional provisions arising out of the Second Act amending regulations on medicinal products and other regulations
Nineteenth sub-chapter
Transitional provision
Section 147Transitional provision arising out of the Third Act amending the regulations on medicinal products and other regulations